Sponsor or institution
Clinical trials and research at Haisco Pharmaceutical Group Co., Ltd.
As of November 12, 2026, Find a Trial lists 28 clinical trials run by Haisco Pharmaceutical Group Co., Ltd. that are recruiting, at sites in 2 countries (most in China (27), Australia (1)). 3 were first registered in the last 30 days. By phase: Phase 1 (14), Phase 2 (6), Phase 3 (5), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 28Clinical trials
- 3New in 30 days
- 2Countries
Newest trials
All recruiting trials (28)
-
Hormone/Drug HSK31858: does it affect the QT interval in healthy adults
This study tests whether HSK31858 changes the QT/QTc interval in healthy Chinese adults aged 18–45.
-
How HSK31858 behaves in people with different kidney function
This study tests how the drug HSK31858 moves through and affects people with mild, moderate, or severe kidney impairment compared to those with normal kidney function, in adults with non-cystic fibrosis bronchiectasis.
-
See if HSK31858 behaves safely in people with different levels of liver function
This study tests how HSK31858 behaves in the body and whether it is safe in adults with normal liver function or with mild to severe liver impairment.
-
HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer
This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.
-
Test of HSK46256, a PARP1 inhibitor, in adults with advanced solid tumors
This early-phase study tests whether the drug HSK46256 is safe and tolerable and how it behaves in the body for adults with advanced solid tumors who have exhausted standard therapies.
-
Long-term safety and effectiveness of HSK39297 tablets in IgA nephropathy patients who completed prior study
This phase 2 trial tests whether taking HSK39297 once daily for IgA nephropathy is safe over the long term and helps reduce protein in the urine for patients who completed a previous study and meet criteria.
-
Safety test of HSK31858 in people with non-cystic fibrosis bronchiectasis
This phase 3 study tests whether HSK31858 is safe for adults with non-cystic fibrosis bronchiectasis who previously participated in the related study.
-
Breathing better with HSK39004: a inhaled medicine tested in COPD patients
This phase 3 trial tests whether inhaled HSK39004 powder helps people with COPD improve breathing compared with a placebo.
-
HSK31679 in MASH: a phase 3 test for safety and liver improvement
This phase 3 trial tests whether HSK31679 helps people with MASH compared to a placebo.
-
First-in-human testing of HSK56630 in healthy adults
This early-phase study tests whether a single dose of HSK56630 is safe and tolerable in healthy adults.
-
HSK42360-Na for advanced or metastatic solid tumors with BRAF V600 mutation
This trial will test whether an oral drug called HSK42360-Na is safe and tolerated in adults with advanced or metastatic solid tumors that carry a BRAF V600 mutation.
-
Pain relief after abdominal surgery: testing HSK55718 against morphine and placebo
We’re testing whether HSK55718 can safely and effectively reduce pain after abdominal surgery, compared with morphine and a placebo.
-
Safety and food-effect testing of HSK55879 tablets in healthy adults
This will test whether HSK55879 tablets are safe, well tolerated, and how food affects their absorption in healthy adults aged 18–45.
-
HSK39297 tablets for adults with primary IgA nephropathy
This trial will try HSK39297 tablets versus placebo to lower proteinuria and protect kidney function in adults with primary IgA nephropathy.
-
HSK39297 tablets for lupus nephritis
This trial will test whether once-daily oral HSK39297 (200 mg or 300 mg) is safe and well tolerated compared with placebo in adults with active lupus nephritis.
-
HSK47388 for adults with moderately to severely active ulcerative colitis
This trial will test whether HSK47388 helps adults with moderately to severely active ulcerative colitis control inflammation and symptoms better than a placebo.
-
HSK47977 tablets for adults with relapsed or refractory non-Hodgkin's lymphoma.
This Phase 1 study will test whether oral HSK47977 tablets are safe, how the body handles them, and whether they help adults with relapsed or refractory non-Hodgkin's lymphoma.
-
HSK42360 treatment for children with malignant brain tumors that have a BRAF V600 mutation
This trial tests whether the oral drug HSK42360 is safe and tolerable in children aged 6 to under 18 who have recurrent malignant brain tumors with a BRAF V600 mutation.
-
How HSK39297 is processed and tolerated in people with mild to moderate liver impairment
This trial tests how the drug HSK39297 is absorbed, cleared, and tolerated in adults with mild to moderate liver impairment compared with people who have normal liver function.
-
Testing HSK39004 inhalers in Chinese COPD patients
A 2nd-phase trial tests whether HSK39004 inhalers (dry powder and inhalation suspension) are safe and help COPD patients in China compared with placebo.
-
HSK46575 for metastatic castration‑resistant prostate cancer
This trial will test an oral drug called HSK46575 for safety, tolerability, and how it behaves in men with metastatic castration‑resistant prostate cancer who have progressed on hormonal therapy and typically chemotherapy.
-
Testing HSK41959 in patients with advanced solid tumors and MTAP deletion
This study is testing a new oral medication called HSK41959 to see if it is safe and tolerable for patients with advanced solid tumors that have a specific gene deletion.
-
Long-term safety and tolerability of HSK39297 for patients with PNH
This study is testing if continuing treatment with HSK39297 is safe and effective for adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have already used this medication.
-
Evaluating the accuracy of cipepofol during general anesthesia in elective surgeries
This study is testing how well a new anesthesia drug called cipepofol works in people having elective surgeries by comparing different doses to see which one is more effective.
-
Assessing a new treatment for non-cystic fibrosis bronchiectasis
This study is testing a new treatment called HSK31858 to see if it can help people with non-cystic fibrosis bronchiectasis feel better and have fewer flare-ups.
-
Testing HSK42360 for solid tumors with BRAF V600 mutation
This study is testing a new oral medication called HSK42360 to see if it is safe and helpful for people with advanced solid tumors that have a specific BRAF V600 mutation.
-
Testing HSK39775 for patients with advanced solid tumors
This study is testing a new drug called HSK39775 to see if it can safely help adults with advanced solid tumors that haven’t responded to other treatments.
-
Testing HSK40118 in patients with advanced lung cancer and EGFR mutations
This study is testing a new oral medication called HSK40118 to see if it is safe and effective for people with advanced lung cancer that has a specific genetic mutation.
Quick answers
How many clinical trials run by Haisco Pharmaceutical Group Co., Ltd. are recruiting right now?
28, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (27 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 14, Phase 2: 6, Phase 3: 5, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.